Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term useKlok, RM., Postma, MJ., Van Hout, BA. & Brouwers, JRBJ., 15-May-2003, In : Alimentary Pharmacology & Therapeutics. 17, 10, p. 1237-1245 9 p.
Research output: Contribution to journal › Article › Academic › peer-review
Background: Proton pump inhibitors have a prominent role in the management of acid-related diseases. Controlling expenses on proton pump inhibitors would yield great economic benefits for Dutch health care.
Aim: To investigate whether clinical differences in proton pump inhibitors exist.
Methods: We searched Medline, EMBASE and the Cochrane Library. We identified papers in English, German, French or Dutch in which two or more proton pump inhibitors were compared under the same clinical conditions in gastro-oesophageal reflux disease, peptic ulcer disease or Helicobacter pylori eradication. The pooled relative risks were calculated using the Mantel-Haenszel method.
Results: Two significant differences were found in the proton pump inhibitors compared. In gastro-oesophageal reflux disease, esomeprazole 40 mg was superior to omeprazole 20 mg (relative risk, 1.18; 95% confidence interval, 1.14-1.23). In peptic ulcer disease, pantoprazole 40 mg was superior to omeprazole 20 mg (relative risk, 1.07; 95% confidence interval, 1.02-1.13). In Helicobacter pylori eradication, no significant differences were found.
Conclusions: Both significant differences found were in favour of the highest dose of proton pump inhibitor on a milligram basis. This indicates that the difference may be dose dependent and not proton pump inhibitor specific. Therefore, when prescribing proton pump inhibitors, arguments other than clinical efficacy, such as those related to pharmaco-economics, may be considered.
|Number of pages||9|
|Journal||Alimentary Pharmacology & Therapeutics|
|Publication status||Published - 15-May-2003|
- HELICOBACTER-PYLORI INFECTION, GASTROESOPHAGEAL REFLUX DISEASE, RANDOMIZED CONTROLLED TRIAL, ACTIVE DUODENAL-ULCER, OMEPRAZOLE 20 MG, TRIPLE THERAPY, DOUBLE-BLIND, EUROPEAN MULTICENTER, RELATIVE EFFICACIES, CLINICAL EFFICACY